Our data suggests that, among the pathways associated with cell-intrinsic PD-L1 signaling, BIM is potentially the underlying mechanism that affects the prognostic role of PD-L1 and mediates cell apoptosis when receiving gefitinib treatment in EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.